Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Abiomed Hits New 52-Week High: 3 Factors Driving the Stock
by Zacks Equity Research
Abiomed (ABMD) recently reported strong preliminary third-quarter fiscal 2018 results.
Zacks.com highlights: Caterpillar, Crocs, Pioneer Natural Resources, Legg Mason and Intuitive Surgical
by Zacks Equity Research
Zacks.com highlights: Caterpillar, Crocs, Pioneer Natural Resources, Legg Mason and Intuitive Surgical
Becton, Dickinson Completes Enrollment in Lutonix DCB Trial
by Zacks Equity Research
Becton, Dickinson's (BDX) focus in the Balloon-Angioplasty space is expected to lend the company a competitive edge in the niche MedTech markets.
Medtronic's FDA Nod for Riptide Aspiration System Boosts RTG
by Zacks Equity Research
Medtronic (MDT) makes efforts to boost RTG business.
Becton, Dickinson Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Becton, Dickinson (BDX) rides on favorable regulatory developments and strategic acquisitions.
5 Top Stocks Powered by Beat Potential This Earnings Season
by Zacks Equity Research
Bet on five stocks that are likely to outdo earnings estimates.
Medtronic (MDT) Wins FDA Nod for New Clinician Programmer
by Zacks Equity Research
Medtronic's (MDT) latest FDA nod likely to boost Pain Therapies division.
5 Reasons Why You Should Offload Wright Medical Stock Now
by Zacks Equity Research
Foreign currency fluctuations and pricing pressure continue to be major headwinds for Wright Medical Group (WMGI).
5 Reasons Why McKesson Deserves a Place in Your Portfolio
by Zacks Equity Research
McKesson (MCK) continues to pursue deals, divestitures and acquisitions to drive growth. The company's impressive performance in 2017 accounts for its potential to sustain the momentum.
Will Intuitive Surgical (ISRG) Disappoint in Q4 Earnings?
by Zacks Equity Research
Intuitive Surgical (ISRG) is expected to witness growth across da Vinci Surgical and Service segments. Instruments and accessories revenues are also expected to increase year over year.
Medtronic's ITB Therapy Superior to CMM for PSS Reduction
by Zacks Equity Research
Medtronic (MDT) consistently tries efforts to boost Pain Therapies division, part of the Restorative Therapies Group.
Myriad Genetics Fortifies Molecular Diagnostics With FDA Nod
by Zacks Equity Research
Myriad Genetics (MYGN) has been leaving no stone unturned to boost the uptake of BRACAnalysis CDx test and strengthen the Molecular Diagnostics portfolio.
QIAGEN Partners DiaSorin, Boosts Molecular Diagnostics Arm
by Zacks Equity Research
QIAGEN (QGEN) continues to adopt initiatives to strengthen Molecular Diagnostics business.
Express Scripts 90-Day Analysis of Opioid Management Positive
by Zacks Equity Research
Express Scripts (ESRX) addresses the national opioid epidemic by reducing excessive and improper opioid use.
Henry Schein (HSIC) Buys ABASE, Expands in Animal Health
by Zacks Equity Research
Henry Schein (HSIC) forges ahead with deals to strengthen the Global Animal Health business.
Baxter (BAX) Launches Arisure Closed System Transfer Device
by Zacks Equity Research
Baxter's (BAX) Arisure Closed System reduces exposure risk of healthcare professionals to needles. Also, the latest development promotes safe handling of hazardous drugs.
Abbott's (ABT) Diabetes Care Unit Strong on FreeStyle Libre
by Zacks Equity Research
Abbott (ABT) forges ahead with initiatives to boost diabetes care. The latest CMS recognition will widen customer base for FreeStyle Libre glucose monitoring system.
Integra LifeSciences Estimates Strong Revenue Figures for Q4
by Zacks Equity Research
Integra LifeSciences (IART) sees strong organic growth in the company's Specialty Surgical Solutions as well as Orthopedics and Tissue Technologies businesses.
Intuitive Surgical (ISRG) Upbeat on Q4 & 2017 Sales Results
by Zacks Equity Research
Intuitive Surgical (ISRG) optimistic about fourth-quarter and 2017 net sales outcome on revenue growth across all business segments.
The Zacks Analyst Blog Highlights: Macy???s, Target, SS&C Technologies, Intuitive Surgical and Brighthouse Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Macy???s, Target, SS&C Technologies, Intuitive Surgical and Brighthouse Financial
Abaxis' (ABAX) Preliminary Results for Q3 Cheer Investors
by Zacks Equity Research
Abaxis (ABAX) expects substantial tax savings from the recent U.S. tax reform.
Hill-Rom (HRC) Estimates Strong Revenue Figures for Q1
by Zacks Equity Research
Hill-Rom (HRC) expects substantial tax savings from the recent U.S. tax reform.
Buy These 3 Stocks on Today's Strong Gains
by Benjamin Rains
The New Year has been dominated by cryptocurrencies and blockchain technology, with unlikely companies such as Kodak (KODK) jumping on the bandwagon after announcing its new KODAKCoin and KODAKOne platform.
NuVasive Q4 Preliminary Results Fail to Cheer Investors
by Zacks Equity Research
NuVasive (NUVA) continues to witness sequential growth in international revenues and expects substantial tax savings from the recent U.S. tax reform.
DexCom Estimates Strong Revenue Figures for Q4 and 2017
by Zacks Equity Research
Dexcom (DXCM) to gain from strong sensor volumes, international revenues and expanding worldwide patient base in 2018.